The

Laboratory Report Winter 2012

A Publication of the Department of Pathology and Genomic Medicine

2

3

4

5

6

Dr. Alberto Ayala Receives Award from MD Anderson

Dr. Suyang Hao Joins Department Faculty

Dr. Youli Zu Receives Grant from National Cancer Institute

New Diagnostic Test Offerings

In Focus: The Renal Pathology Team

Lab Stats: Methodist West Houston Hospital

Dr. Muthiah Kumaraswami Receives Grant From American Heart Association

Trainee Spotlight

Office of Academic Development to Hold Additional Seminars

Table of Contents

Methodist Pathology and Pharmacy Partner to Reduce Length of Stay

To register, visit texpath.org. The abstract submission deadline has passed.

To register, visit uscap.org. The abstract submission deadline has passed.

102nd Annual Meeting

Baltimore Convention

Center

Baltimore, Maryland

March 2-8, 2013

T he Methodist Hos-

pital System De-

partment of Pathol-

ogy and Genomic Medi-

cine is once again leading

medicine with the imple-

mentation of a new inter-

vention that significantly

reduces the length of hos-

pitalization for patients

with Gram-negative

bloodstream infections. The

new process combines rapid

identification of bacteria

using matrix-assisted laser desorption

ionization-time of flight (MALDI-TOF)

mass spectrometry and streamlined an-

timicrobial susceptibility testing, in con-

junction with near-real-time antimicrobial

stewardship practices.

This novel intervention was developed

here at Methodist by Dr. Katherine Perez,

a clinical specialist in the Pharmacy De-

partment, and members of the Clinical

Microbiology Laboratory, Pharmacy

Department, and the Center for Biostatis-

tics at The Methodist Hospital Research

Institute.

“This new method is as accurate as the

old method, and takes less than half the

time,” said Dr. James Musser, chair of the

Department of Pathology and Genomic

Medicine for the system and a co-

investigator on the study. “Time is espe-

cially important when infections become

systemic. Getting patients on the most

effective therapy as

quickly as possible is

critical.”

The collaborating team

conducted a clinical study

at Methodist to assess the

new intervention, and

confirmed that it signifi-

cantly improved the time

to optimal therapy and

decreased hospital length-

of-stay and costs. The re-

sults of the study were

published in an early

online release in Archives of Pathology and

Laboratory Medicine.

For more information on the interven-

tion, contact Pat Cernoch in the Clinical

Microbiology Laboratory at 713-441-0333.

For more information on the Express

Blood Culture Service offered by

Methodist Diagnostic Laboratories or to

subscribe to the service for your non-

Methodist hospital, contact Phuong

Nguyen at ptnguyen@tmhs.org.

The

Laboratory Report View archive issues at methodisthealth.com/TheLaboratoryReport

Study investigators pose with the Bruker mass spectrometer. From left, Dr. William Musick, Dr. James Musser, Dr. Katherine Perez, Pat Cernoch, Dr. James Davis,

Dr. Geoffrey Land, Dr. Leif Peterson, and Dr. Randall Olsen.

The

LABORATORY REPORT

2

Dr. Suyang Hao Joins Department Faculty

T he Department’s Hematopathol-

ogy service added its newest fac-

ulty member on October 1st. Dr.

Suyang Hao comes to Methodist from the

Department of Pathology at the Univer-

sity of Massachusetts Medical School and

the UMass Memorial Medical Center in

Worcester, Massachusetts, where she was

an associate professor and director of the

Flow Cytometry Laboratory and Hemato-

pathology Fellowship Program.

“Dr. Hao brings an impressive range

and depth of experience to the Depart-

ment,” said Dr. James Musser, chair of

the Department of Pathology and Ge-

nomic Medicine for The Methodist Hos-

pital System. “Her contributions to our

patients and our academic programs will

be greatly appreciated.”

Dr. Hao received her M.D. degree in

1983 from the Tianjin Medical University

in Tianjin, China. She completed her pa-

thology residency at the University of

Kansas Medical Center in Kansas City,

Kansas, and a hematopathology fellow-

ship at the William Beaumont Hospital in

Royal Oak, Michigan. Dr. Hao joined the

Department of Pathology at the Univer-

sity of Massachusetts Medical School in

2003.

For more information on Dr. Hao, visit

methodisthealth.com/hao.

Suyang Hao, M.D.

D r. Alberto Ayala, deputy chief

of pathology for the Depart-

ment, has received the Distin-

guished Alumnus Award from The Uni-

versity of Texas MD Anderson Cancer

Center. He was presented with the pres-

tigious award at a ceremony and lecture

at MD Anderson on December 6th.

“The Department and the Hospital

System congratulate Dr. Ayala,” said Dr.

James Musser, chair of the Department of

Pathology and Genomic Medicine for the

System. “This level of recognition is re-

markable and a testament to his im-

mense career accomplishments.”

The Distinguished Alumnus Award

was established at MD Anderson in 1980

to recognize a prominent individual who

had trained at the Center and made

Dr. Alberto Ayala Receives Award from MD Anderson

distinguished contributions to their re-

spective field.

Dr. Ayala received his M.D. degree

from the University of Nuevo Leon

School of Medicine in Monterrey, Mexico

in 1960. He completed pathology resi-

dency at The University of Texas Medical

Branch at Galveston, and a fellowship at

MD Anderson where he joined the fac-

ulty in 1968. Dr. Ayala joined the pathol-

ogy department at Methodist in 2004.

For more information on Dr. Ayala,

visit methodisthealth.com/ayala.

Alberto G. Ayala, M.D.

The

LABORATORY REPORT

3

Dr. Youli Zu Receives Grant from National Cancer Institute

D r. Youli Zu, co-director of He-

matopathology for the Depart-

ment, has received a $1 million

R33 grant from the National Cancer In-

stitute (NCI) to develop and validate an

assay for the detection of circulating tu-

mor cells.

“Early detection of cancer and real-

time assessment of response to treatment

are critical in improving patient out-

comes,” said Dr. Zu. “This test will be a

great advance over the existing test, and

will allow for earlier detection and more

accurate results.”

The proposed assay will allow physi-

cians to detect circulating tumor cells in

one drop of patient blood and provide

results in seconds. The “one-drop, one-step”

V on Willebrand disease is the

most common hereditary coagu-

lation disorder. It is caused by a

deficiency and/or malfunctioning of von

Willebrand factor, a protein required for

platelet adhesion and hemostasis. The

Department of Pathology and Genomic

Medicine has recently brought three new

assays in-house to test for von Wille-

brand disease.

Von Willebrand Factor Collagen

Binding Assay

When tissue is damaged or wounded,

collagen is exposed to blood, and the von

Willebrand factor in blood adheres to the

collagen and pulls platelets from the

blood to start the hemostasis process.

This assay mimics this wound process to

determine the amount of and collagen

binding ability of von Willebrand factor.

In can be used to help differentiate type 1

from type 2 von Willebrand disease.

Von Willebrand Factor Immunofunc-

tional Activity Assay

The GP1b binding domain is responsi-

ble for facilitating the proper binding of

New Diagnostic Test Offerings:

platelets with von Willebrand factor. This

assay uses a monoclonal antibody to de-

termine if the GP1b binding domain is

functioning properly. This assay measures

the amount of and GP1 binding site func-

tion of von Willebrand factor in blood.

Von Willebrand Factor Multimer Assay

Normal von Willebrand factor is com-

posed of large protein polymers with

high molecular weight. This test is a

Western blot assay that evaluates

whether the patient is making these nor-

mal, large polymers.

The Methodist Hospital is the only pro-

vider of the multimer assay in Texas.

Combined, these assays establish Meth-

odist as having the most comprehensive

von Willebrand disease panel available in

the state.

For more information regarding von

Willebrand disease testing at Methodist,

contact Dr. Wayne Chandler at wlchan-

dler@tmhs.org. To subscribe to the von

Willebrand testing services for your non-

Methodist hospital, please contact

Phuong Nguyen at Methodist Diagnostic

Laboratories at ptnguyen@tmhs.org.

Western blot multimer assay results showing absence of normal von

Willebrand polymers.

system that is only activated in the pres-

ence of tumor cells. The current assay is

both time and labor intensive, requiring

significantly more blood and several

preparation steps to isolate and stain the

tumor cells. Tumor cells can be lost dur-

ing these steps, reducing the accuracy of

the assay.

In addition to his responsibilities as co-

director of Hematopathology for the De-

partment, Dr. Zu is also the director of

the Cancer Pathology Laboratory at The

Methodist Hospital Research Institute

where the R33 grant is based.

For more information on Dr. Zu, visit

methodisthealth.com/Zu.

Dr. Zu at The Methodist Hospital Research Institute

assay will use unique aptamer probes,

developed with Dr. Zu’s previous R43

grant from the NCI, that carry a reporter

The

LABORATORY REPORT

4

In Focus: The Renal Pathology Team

R enal pathology, or nephropathol-

ogy, is the subspecialty of anat-

omic pathology that focuses spe-

cifically on the study of diseases of kid-

ney tissue, including conditions related

to kidney transplant. These studies are

usually conducted on tissues obtained

through percutaneous renal biopsy. In

addition to light microscopy, renal pa-

thologists also use transmission electron

microscopy and immunofluorescence to

render a diagnosis.

The Department of Pathology and Ge-

nomic Medicine has a team of three anat-

omic pathologists with special training

and expertise in renal pathology. This team

Luan D. Truong, M.D.

Medical Director, Renal Pathology

Dr. Truong received his M.D. degree

from the Pennsylvania State University

College of Medicine in 1979. He com-

pleted pathology residency at Baylor Col-

lege of Medicine in Houston, and a renal

pathology fellowship at Columbia Uni-

versity in New York. His research aims to

better understand chronic tubulointersti-

tial injury using models of chronic ob-

structive nephropathy and ischemia-

reperfusion injury.

For more information on Dr. Truong,

visit methodisthealth.com/Truong.

Roberto Barrios, M.D.

Associate Medical Director, Renal Pathology

Dr. Barrios received his M.D. degree

from the Facultad de Medicina, Universi-

dad Nacional Autonoma de Mexico in

Mexico City in 1969. He then completed

pathology residency at the University

Hospitals of Cleveland and a renal pa-

thology fellowship at the Children’s Hos-

pital and National Heart Institute in Mex-

ico City. Dr. Barrios also completed a

pulmonary pathology fellowship at the

Lyman Duff Laboratory of McGill Uni-

versity and Royal Victoria Hospital in

Montreal, Quebec, Canada.

For more information on Dr. Barrios,

visit methodisthealth.com/Barrios.

provides invaluable

support to the ne-

phrology service

and transplant cen-

ter at Methodist, and

at other institutions

served by Methodist

Diagnostic Labora-

tories. The renal

pathology team also

provides outstanding

mentoring opportuni-

ties for the residents and fellows in the

Department of Pathology and Genomic

Medicine.

The renal pathology team: from left, Drs. Roberto Barrios, Luan Truong, and Lillian Gaber.

Lillian W. Gaber, M.D.

Associate Medical Director, Renal Pathology

Dr. Gaber received her medical degree

from the Ain Shams University School of

Medicine in Cairo, Egypt in 1976. She

completed residencies in anatomic and

clinical pathology at the New England

Deaconess Hospital in Boston, and a fel-

lowship in perinatal obstetrics and gyne-

cology pathology at the Brigham and

Women’s Hospital, also in Boston. Her

research investigates donor kidney biop-

sies at the cellular and molecular level to

determine suitability for transplantation,

changes following organ reperfusion, and

efficacy of immunosuppressive therapies.

For more information on Dr. Gaber,

visit methodisthealth.com/LillianWGaber. For more information on the renal pa-

thology service at Methodist, please con-

tact Dr. Luan Truong at ltruong@tmhs.org.

Dr. Truong (right), and technologist Claire Haueter, review a kidney biopsy using the

transmission electron microscope.

Dr. Barrios (left) mentors resident, Dr. Jordan Roberts.

Dr. Gaber (center) consults on a kidney transplant patient with Dr. A. Osama Gaber (left)

and Dr. Samir Patel.

The

LABORATORY REPORT

5

“West Houston is growing fast and so is our hospital. Our team works hard to meet the challenges that new and grow-ing service lines bring. We like those chal-lenges; they energize us.”

Thu Ngo, M.D.

Lab Stats: Methodist West Houston Hospital Medical Director: Thu Ngo, M.D.

Dr. Ngo received his M.D. degree from

the Baylor College of Medicine in Hous-

ton in 1995. He completed a pathology

residency and fellowships in cytopathol-

ogy, hematopathology, and transfusion

medicine there as well. Dr. Ngo became

the medical director of Laboratory Ser-

vices at Methodist West Houston Hospi-

tal when the hospital opened in 2010.

Faculty: Lauri B. Campagna, M.D.

Dr. Campagna received her M.D. de-

gree in 1991 from the University of Colo-

rado School of Medicine in Denver. She

completed a residency in anatomic and

clinical pathology and a fellowship in

cytopathology at the Baylor College of

Medicine in Houston.

Dr. Campagna spent ten years in com-

munity hospital pathology, including as

the hospital chief of staff at the Medical

Center of Mckinney in McKinney, Texas.

She then held the appointment of assis-

tant professor of surgical pathology at

The University of Texas Southwestern

Medical Center in Dallas before joining

the laboratory at Methodist West Hous-

ton Hospital in 2011.

Pictures from top: Dr. Ngo in the Core Laboratory; Dr. Campagna in the Histology Laboratory; Melody Peeples processing hematopathology specimens; Ericka Bonnee logging in specimens;

and Joy Nunez loading the coagulation analyzer.

“It‟s been wonderful to return to Hous-ton and The Methodist Hospital System. The Katy area is vibrant and growing; it‟s a great place to be.”

Lauri B. Campagna, M.D.

Director: Melody Peeples, B.S., M.Ed.

Ms. Peeples received her master of edu-

cation (higher education administration

and supervision) from the University of

Houston and her bachelor of science

(medical technology) from Eastern Illi-

nois University. In addition to being the

director of laboratory services at Meth-

odist West Houston Hospital, she is also

the director of respiratory care.

“With expansion of our cardiovascular surgery program, opening of another medi-cal/surgical unit, and the addition of beds in our Family Birthing Center and NICU, the belief of „build it and they will come‟ is being fulfilled. Our team has successfully met each challenge with enthu-siasm and demonstration of our ICARE values.”

Melody Peeples, B.S., M.Ed.

Staff:

The laboratory currently employs 22

staff members that include laboratory

technicians, medical technologists, histol-

ogy assistants, and laboratory service

center representatives. These employees

work together to adapt to the fast-

growing environment of Methodist West

Houston Hospital. They are the A-team

of West Houston.

“It‟s always changing, but that is good; it keeps you on your toes.”

Joy Nunez, MT Q.A. Specialist and ICARE Award Recipient

“This is a nice place to work. We all work well together.”

Ericka Bonnee Laboratory Service Center Representative

The

LABORATORY REPORT

6

Trainee Spotlight:

Jian Chen, M.D., Ph.D. PGY4 Resident

D r. Jian Chen, PGY4 clinical pathology resident, is the recipient of the Department’s

Trainee Leadership and Innovation Award for the 4th quarter of 2012. He re-

ceived the award for initiating and conducting a stem cell donation study with Dr.

Christopher Leveque that resulted in a Fenwal Award from the American Association of

Blood Banks. Dr. Chen will also be presenting a poster on partial e antibody at the Texas

Society of Pathologists’ 92nd Annual Meeting in Austin in January.

Dr. Chen received his medical degree from the Shandong Medical University in China and

his Ph.D. in molecular and cellular pathology from the University of Alabama at Birming-

ham. He completed a blood banking/transfusion medicine fellowship at Methodist last year. Jian Chen, M.D., Ph.D.

Dr. Muthiah Kumaraswami Receives Grant from American Heart Association

D r. Muthiah Kumaras-

wami, an investigator

in the Department’s

Center for Molecular and Trans-

lational Human Infectious Dis-

eases Research, has received a 4-

year Scientist Development

Grant from the American Heart

Association to study the effect of

gene regulation on virulence in

group A Streptococcus.

“These bacteria cause a wide

range of infections, and some

can be very serious,” said Dr.

Kumaraswami. “Understanding

why some Streptococcus infec-

tions are more severe than others

is important, and will help us

develop more effective treatments.”

Group A Streptococcus causes a broad

range of clinical manifestations, from

mild pharyngitis and impetigo to

life threatening flesh-eating dis-

ease and toxic shock syndrome.

Post-infection sequelae can also

include acute rheumatic heart

disease, the leading cause of

cardiovascular morbidity and

mortality in young people in

developing countries.

In the proposed studies, Dr.

Kumaraswami will use genetic,

biochemical, biophysical, and

crystallographic methods to

elucidate the role of growth-

phase-specific secreted small

peptides as potential intercellu-

lar signals in the gene regulation

of Streptococcus virulence.

For more information on Dr. Kumaras-

wami, visit methodisthealth.com/

Kumaraswami.

Dr. Kumaraswami (right), with Senior Research Technician Nishanth Makthal, in their laboratory at The Methodist Hospital Research Institute.

Office of Academic Development to Hold Additional Seminars

T he Office of Academic Devel-

opment (OAD) in the Depart-

ment of Pathology and Ge-

nomic Medicine has scheduled its

seminars and workshops for 2013.

“These seminars can be very help-

ful to trainees and junior faculty,”

said Dr. Kathryn Stockbauer, man-

ager of the OAD. “It gives them the

information they need to „jump start‟

their academic development and

really get moving with their pro-

jects.”

The OAD will hold 2 one-hour seminars

in the first quarter of 2013. These

seminars will cover research creden-

tialing, ARAF/IRB submissions, and

study design (Jan. 15), and scientific

writing and presentations (Mar. 12).

A more interactive workshop on

manuscript development will be held

in April. That workshop will last

approximately 2 hours, and attendees

will bring actual manuscripts in

preparation to further develop with

the instructor.

For more information on the OAD,

visit methodisthealth.com/OAD.

Dr. Stockbauer leading a scientific writing seminar with trainees in 2011.

The

LABORATORY REPORT

Cagle PT. The transformation of pathology: proceedings of the Houston Lung Symposium. Arch Pathol Lab Med. 2012 Oct;136(10):1184

-5.

Cagle PT, Myers J. Precision medicine for lung cancer: role of the surgical pathologist. Arch Pathol Lab Med. 2012 Oct;136(10):1186-9.

Choi E, Lewis AL, Takei H, Ro JY. Leptomeningeal carcinomatosis as initial presentation in adenocarcinoma of lung with signet ring

cell features: an autopsy case report. Int J Clin Exp Pathol. 2012;5(9):972-6.

Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, Rainusso N, Wu MF, Liu H, Kew Y, Grossman RG, Powell S, Lee D, Ah-

med N, Gottschalk S. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2012 Oct 16. [Epub ahead of print]

Crombet O, Lastrapes K, Zieske A, Morales-Arias J. Complete morphologic and molecular remission after introduction of dasatinib in

the treatment of a pediatric patient with T-cell acute lymphoblastic leukemia and ABL1 amplification. Pediatr Blood Cancer. 2012

Aug;59(2):333-4.

Eison TM, Hastings MC, Moldoveanu Z, Sanders JT, Gaber L, Walker PD, Lau KK, Julian BA, Novak J, Wyatt RJ. Association of IgG

co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy. Clin Nephrol. 2012 Dec;78(6):465-9.

Flores AR, Jewell BE, Fittipaldi N, Beres SB, Musser JM. Human disease isolates of serotype M4 and M22 group A Streptococcus lack

genes required for hyaluronic acid capsule biosynthesis. MBio. 2012 Nov 6;3(6).

Gulmann C, Paner GP, Parakh RS, Hansel DE, Shen SS, Ro JY, Annaiah C, Lopez-Beltran A, Rao P, Arora K, Cho Y, Herrera-

Hernandez L, Alsabeh R, Amin MB. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcino-

mas of urothelial tract. Hum Pathol. 2012 Sep 17. [Epub ahead of print]

Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, Zhao W, Moore DH, Powell SZ, Appel SH. Regulatory T-

lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2012 Nov 9. [Epub ahead of print]

Khan KA, Smith DA, Thrall MJ. Only a small fraction of high-grade cervical lesions are discovered after an interpretation of atypical

squamous cells of undetermined significance when using imager-assisted, liquid-based Papanicolaou tests and the Bethesda 2001

System. Arch Pathol Lab Med. 2012 Sep 20. [Epub ahead of print]

Kim NR, Hyun Yee Cho HY, Piña-Oviedo S, De La Roza G, Lee YD, Ro JY. Follicular adenoma with extensive extracellular mucin

deposition: report on two cases. Clin Med Insights Case Rep 2012; 5:155–162.

Kim MJ, Shin HC, Shin KC, Ro JY. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma

of lung: tissue microarray assay in resected lung cancer specimens. Ann Diagn Pathol. 2012 Oct 3. [Epub ahead of print]

Li Y, Shaw CA, Sheffer I, Sule N, Powell SZ, Dawson B, Zaidi SN, Bucasas KL, Lupski JR, Wilhelmsen KC, Doody R, Szigeti K. Inte-

grated copy number and gene expression analysis detects a CREB1 association with Alzheimer's disease. Transl Psychiatry. 2012 Nov

20;2:e192.

Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. Test variability of the Quantiferon-TB Gold In-Tube Assay

in clinical practice. Am J Respir Crit Care Med. 2012 Oct 26. [Epub ahead of print]

Mishra DK, Sakamoto JH, Thrall MJ, Baird BN, Blackmon SH, Ferrari M, Kurie JM, Kim MP. Human lung cancer cells grown in an ex

vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One. 2012;7(9):e45308.

Pagano MB, Chandler WL. Bleeding risks and response to therapy in patients with INR higher than 9. Am J Clin Pathol. 2012 Oct;138

(4):546-50.

Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairn-

cross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green

RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Initial treatment patterns over time for anaplas-

tic oligodendroglial tumors. Neuro Oncol. 2012 Jun;14(6):761-7.

Perez KK, Olsen RJ, Musick WL, Cernoch PL, Davis JR, Land GA, Peterson LE, Musser JM. Integrating rapid pathogen identification

and antimicrobial stewardship significantly decreases hospital cost. Arch Pathol Lab Med. 2012 Dec 6. [Epub ahead of print]

Song JS, Song DE, Kim KR, Ro JY. Cellular pseudosarcomatous fibroepithelial stromal polyp of the vagina during pregnancy: a lesion

that is overdiagnosed as a malignant tumor. Korean J Pathol. 2012;46(5):494-8.

Continued page 8

RECENT PUBLICATIONS

7

The

LABORATORY REPORT

Ping Wang, Ph.D. Claudia P. Molina, M.D.

Seema Mullick, M.D.

Thu Ngo, M.D.

Steven Shen, M.D., Ph.D.

Paul Sumby, Ph.D.

The Laboratory Report is a publication

of The Methodist Hospital System

Department of Pathology and

Genomic Medicine.

Treviño J, Liu Z, Cao TN, Ramirez-Peña E, Sumby P. RivR is a negative regulator of virulence factor expression in the group A Strep-

tococcus. Infect Immun. 2012 Nov 12. [Epub ahead of print]

Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Dybkaer K, Chiu A,

Orazi A, Zu Y, Bhagat G, Wang HY, Dunphy CH, O' Neill S, Hsi ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Ai W,

Ponzoni MA, Ferreri AJ, Kahl BS, Winter JN, Go RS, Dirnhofer S, Piris MA, Møller MB, Wu L, Medeiros LJ, Young KH. Patients with

diffuse large B cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a

report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2012 Aug 28. [Epub ahead of print]

Xiao YL, Kash JC, Beres SB, Sheng ZM, Musser JM, Taubenberger JK. High-throughput RNA sequencing of a formalin-fixed, paraffin-

embedded autopsy lung tissue sample from the 1918 influenza pandemic. J Pathol. 2012 Nov 26. [Epub ahead of print]

Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Rich-

ards KL, Hsi ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Kahl BS, Win-

ter JN, Xu W, Li J, Go RS, Li Y, Piris MA, Møller MB, Miranda RN, Abruzzo LV, Medeiros LJ, Young KH. Mutational profile and prog-

nostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Ri-

tuximab-CHOP Consortium Program Study. Blood. 2012 Nov 8;120(19):3986-96.

RECENT PUBLICATIONS continued

8

Editor-in-Chief

April A. Ewton, M.D.

The Laboratory Report

Editorial Committee

Hazel L. Awalt, M.D.

Christopher Leveque, M.D.

The Methodist Hospital

Clare Rose, M.B.A.

Manuel Hinojosa, M.H.A. Editorial Coordinator

Philip Randall

Department Chair

James M. Musser, M.D., Ph.D.